{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,21]],"date-time":"2026-11-21T05:18:08Z","timestamp":1795238288383,"version":"4.10.3"},"reference-count":0,"publisher":"Bentham Science Publishers Ltd.","issue":"6","content-domain":{"domain":["eurekaselect.com"],"crossmark-restriction":true},"short-container-title":["CN"],"published-print":{"date-parts":[[2021,5,27]]},"abstract":"<jats:sec>\n<jats:title>Background:<\/jats:title>\n<jats:p>A dysfunction in glutamate neurotransmission is critical for seizure. Glutamate\nis the major excitatory drive in the cerebral cortex, where seizures occur. Glutamate acts via\n(i) ionotropic (iGlu) receptors, which are ligand-gated ion channels mediating fast excitatory synaptic\ntransmission; and (ii) G proteins coupled metabotropic (mGlu) receptors.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Objective:<\/jats:title>\n<jats:p>To overview the evidence on the role of iGlu receptors in the onset, duration, and severity\nof convulsive and non-convulsive seizures to lay the groundwork for novel strategies for drug-resistant\nepilepsy.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Methods:<\/jats:title>\n<jats:p> We used PubMed crossed-search for \u201cglutamate receptor and epilepsy\u201d (sorting 3,170 reports), searched for \u201cionotropic glutamate receptors\u201d, \u201cAMPA receptors\u201d, \u201cNMDA receptors\u201d, \u201ckainate receptors\u201d, \u201cconvulsive seizures\u201d, \u201cabsence\nepilepsy\u201d, and selected those papers focusing this Review\u2019s scope.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Results:<\/jats:title>\n<jats:p> iGlu receptor antagonists inhibit, whereas agonists worsen experimental seizures in various\nanimal species. Clinical development of iGlu receptor antagonists has been limited by the occurrence\nof adverse effects caused by inhibition of fast excitatory synaptic transmission. To date,\nonly one drug (perampanel) selectively targeting iGlu receptors is marketed for the treatment of focal\nepilepsy. However, other drugs, such as topiramate and felbamate, inhibit iGlu receptors in addition\nto other mechanisms.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Conclusion:<\/jats:title>\n<jats:p> This review is expected to help dissecting those steps induced by iGlu receptors activation, which may be altered to provide antiepileptic efficacy without altering key physiological brain functions, thus improving safety and tolerability of iGlu-receptor directed antiepileptic agents. This effort mostly applies to drug resistant seizures, which impact the\nquality of life and often lead to status epilepticus, which is a medical urgency. <\/jats:p>\n<\/jats:sec>","DOI":"10.2174\/1570159x18666200831154658","type":"journal-article","created":{"date-parts":[[2020,9,1]],"date-time":"2020-09-01T09:41:26Z","timestamp":1598953286000},"page":"747-765","update-policy":"https:\/\/doi.org\/10.2174\/bsp_crossmark_policy","source":"Crossref","is-referenced-by-count":22,"title":["Targeting Ionotropic Glutamate Receptors in the Treatment of Epilepsy"],"prefix":"10.2174","volume":"19","author":[{"given":"Roberta","family":"Celli","sequence":"first","affiliation":[{"name":"I.R.C.C.S. Neuromed, Pozzilli, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Fornai","sequence":"additional","affiliation":[{"name":"I.R.C.C.S. Neuromed, Pozzilli, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"965","container-title":["Current Neuropharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/eurekaselect.com\/article\/download\/185436","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/185436\/article","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/eurekaselect.com\/article\/download\/185436","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,28]],"date-time":"2021-05-28T06:08:06Z","timestamp":1622182086000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.eurekaselect.com\/185436\/article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,5,27]]},"references-count":0,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2021,5,27]]}},"alternative-id":["LiveAll1"],"URL":"https:\/\/doi.org\/10.2174\/1570159x18666200831154658","relation":{},"ISSN":["1570-159X"],"issn-type":[{"value":"1570-159X","type":"print"}],"subject":[],"published":{"date-parts":[[2021,5,27]]},"assertion":[{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Single blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"value":"2020-07-09","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-08-05","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-08-18","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-05-27","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}